These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31746561)

  • 1. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
    Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
    Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
    VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
    J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
    Heltshe SL; Russell R; VanDevanter DR; Sanders DB
    J Cyst Fibros; 2023 Sep; 22(5):864-867. PubMed ID: 36803635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous glucose monitoring indices predict poor FEV
    Pallin M; Kumar S; Daley C; Dawadi S; Leong P; Carr E; Soldatos G
    J Cyst Fibros; 2021 Sep; 20(5):785-791. PubMed ID: 33781701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
    Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
    Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV
    McColley SA; Konstan MW; Ramsey BW; Stuart Elborn J; Boyle MP; Wainwright CE; Waltz D; Vera-Llonch M; Marigowda G; Jiang JG; Rubin JL
    J Cyst Fibros; 2019 Jan; 18(1):94-101. PubMed ID: 30146268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
    Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
    J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
    McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
    Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
    [No Abstract]   [Full Text] [Related]  

  • 10. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
    Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
    Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
    Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
    Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).
    Gold LS; Patrick DL; Hansen RN; Goss CH; Kessler L
    J Cyst Fibros; 2019 Nov; 18(6):886-893. PubMed ID: 31126901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.
    Sanders DB; Zhao Q; Li Z; Farrell PM
    Pediatr Pulmonol; 2017 Oct; 52(10):1268-1275. PubMed ID: 28881091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes.
    Thornton CS; Magaret AS; Carmody LA; Kalikin LM; Simon RH; LiPuma JJ; Caverly LJ
    J Cyst Fibros; 2024 Mar; 23(2):321-328. PubMed ID: 37244842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor.
    Flume PA; Wainwright CE; Elizabeth Tullis D; Rodriguez S; Niknian M; Higgins M; Davies JC; Wagener JS
    J Cyst Fibros; 2018 Jan; 17(1):83-88. PubMed ID: 28651844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
    VanDevanter DR; Heltshe SL; Hilliard JB; Konstan MW
    J Cyst Fibros; 2021 Mar; 20(2):257-263. PubMed ID: 32505525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: A retrospective cohort study.
    Emiralioğlu N; Çakır B; Sertçelik A; Yalçın E; Kiper N; Şen V; Altıntaş DU; Serbes M; Çokuğraş H; Kılınç AA; Başkan AK; Hepkaya E; Yazan H; Türel Ö; Kafi HM; Yılmaz Aİ; Ünal G; Çağlar T; Damadoğlu E; Irmak İ; Demir E; Öztürk G; Bingöl A; Başaran E; Sapan N; Aslan AT; Asfuroğlu P; Harmancı K; Köse M; Hangül M; Özdemir A; Tuğcu G; Polat SE; Özcan G; Gayretli ZG; Keskin Ö; Bilgiç S; Yüksel H; Özdoğan Ş; Topal E; Çaltepe G; Can D; Ekren PK; Kılıç M; Süleyman A; Eyüboğlu TŞ; Cinel G; Pekcan S; Çobanoğlu N; Çakır E; Özçelik U; Doğru D
    Pediatr Pulmonol; 2024 Nov; 59(11):2956-2966. PubMed ID: 38980199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home-spirometry exacerbation profiles in children with cystic fibrosis.
    Bouteleux B; Beaufils F; Fayon M; Bui S
    Pediatr Pulmonol; 2024 Mar; 59(3):552-561. PubMed ID: 38014613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
    Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
    Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.